Chondromyxoid fibroma: A retrospective evaluation of 31 cases
Mustafa Onur Karaca1, Mustafa Özyıldıran2, Rauf Alizade1, Kerem Başarır3, Hüseyin Yusuf Yıldız1
1Department of Orthopedics and Traumatology, Ankara University Faculty of Medicine, Ankara, Türkiye
2Department of Orthopedics and Traumatology, Sandıklı State Hospital, Afyonkarahisar, Türkiye
3Department of Orthopedics and Traumatology, Private Orthopedic Surgeon, Ankara, Türkiye
Keywords: Adjuvant therapy, bone cement, bone graft, chondromyxoid fibroma, intralesional curettage, recurrence.
Abstract
Objectives: This study aimed to review a 35-year experience with chondromyxoid fibroma at our institution.
Patients and methods: The study retrospectively analyzed the records of 31 consecutive patients (17 males, 14 females; mean age: 30.5±15.7 years; range, 6 to 63 years) with chondromyxoid fibroma who were treated between January 1988 and December 2021. The clinical and radiological characteristics of lesions, tumor volume, and recurrence rates were assessed using the tumor archive of the hospital.
Results: The mean follow-up duration was 65.9±42.0 months. Pelvis, proximal tibia, and distal femur were the most common sites of localization. The initial surgical treatment was performed on 27 patients at our clinic, while four patients were referred to the clinic after recurrence. The overall recurrence rate was 16.1%. Intralesional curettage was applied to 21 (77.8%) out of 27 patients. The cavity created after curettage was filled with bone graft (autograft or allograft) in 15 (55.5%) cases. Bone cement was applied in four (14.8%) cases. Resection was applied to five (18.5%) patients. In two (7.4%) cases, intralesional curettage alone was performed. One of these two patients experienced recurrence, resulting in a recurrence rate of 50% in this patient group. No recurrence was observed in other treatment groups.
Conclusion: Intralesional curettage and filling the defect with bone graft or cement were effective for local control in most cases. Curettage alone was associated with high recurrence rates.
Citation: Karaca MO, Özyıldıran M, Alizade R, Başarır K, Yıldız HY. Chondromyxoid fibroma: A retrospective evaluation of 31 cases. Jt Dis Relat Surg 2024;35(2):377-385. doi: 10.52312/jdrs.2024.1620.
The study protocol was approved by the Ankara University Faculty of Medicine Ethics Committee (date: 09.02.2022, no: İ01-55-22). The study was conducted in accordance with the principles of the Declaration of Helsinki.
A written informed consent was obtained from the patients and/or parents of the patients.
Idea/concept: M.O.K., K.B., H.Y.Y.; Design: M.O.K., M.Ö.; Data collection/processing: M.Ö., R.A.; Analysis/interpretation: M.Ö., R.A.; Literature review: M.Ö., R.A.; Drafting/writing: M.O.K., M.Ö.; Control and critical review: M.O.K., H.Y.Y.
The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.
The authors received no financial support for the research and/or authorship of this article.
The data that support the findings of this study are available from the corresponding author upon reasonable request.